资源类型

期刊论文 22

年份

2023 4

2022 1

2020 1

2017 1

2016 3

2015 2

2014 3

2013 2

2011 1

2009 2

2008 1

展开 ︾

关键词

2型糖尿病 1

三维视觉知识;三维参数模型;心脏病理诊断;数据增强 1

临床可行性 1

乙酰肝素酶 1

半衰期 1

基因治疗 1

干细胞 1

心肌梗死 1

心肌适应 1

心脏代谢 1

心脏再生 1

成纤维细胞生长因子21 1

末端疼痛性刺激 1

生物材料 1

电子疗法 1

神经和分子机制 1

糖尿病性心肌病 1

组织工程 1

脂蛋白脂肪酶 1

展开 ︾

检索范围:

排序: 展示方式:

Distinct mononuclear diploid cardiac subpopulation with minimal cell–cell communications persists in

《医学前沿(英文)》   页码 939-956 doi: 10.1007/s11684-023-0987-9

摘要: A small proportion of mononuclear diploid cardiomyocytes (MNDCMs), with regeneration potential, could persist in adult mammalian heart. However, the heterogeneity of MNDCMs and changes during development remains to be illuminated. To this end, 12 645 cardiac cells were generated from embryonic day 17.5 and postnatal days 2 and 8 mice by single-cell RNA sequencing. Three cardiac developmental paths were identified: two switching to cardiomyocytes (CM) maturation with close CM–fibroblast (FB) communications and one maintaining MNDCM status with least CM–FB communications. Proliferative MNDCMs having interactions with macrophages and non-proliferative MNDCMs (non-pMNDCMs) with minimal cell–cell communications were identified in the third path. The non-pMNDCMs possessed distinct properties: the lowest mitochondrial metabolisms, the highest glycolysis, and high expression of Myl4 and Tnni1. Single-nucleus RNA sequencing and immunohistochemical staining further proved that the Myl4+Tnni1+ MNDCMs persisted in embryonic and adult hearts. These MNDCMs were mapped to the heart by integrating the spatial and single-cell transcriptomic data. In conclusion, a novel non-pMNDCM subpopulation with minimal cell–cell communications was unveiled, highlighting the importance of microenvironment contribution to CM fate during maturation. These findings could improve the understanding of MNDCM heterogeneity and cardiac development, thus providing new clues for approaches to effective cardiac regeneration.

关键词: mononuclear diploid cardiomyocytes     cell–cell communication     cardiac fibroblast     single-cell RNA sequencing     cardiac regeneration    

Integrated management of cardiac failure: the cardiac failure clinic

null

《医学前沿(英文)》 2011年 第5卷 第1期   页码 20-25 doi: 10.1007/s11684-011-0106-1

摘要:

The prevalence of the risk factors and the risk of cardiac failure are both increasing in China. This might be the consequence of the changes of the life conditions (emigration to the urban areas, changes in the diet and life style, lack of physical exercise, etc.). The wide range of clinical presentations of cardiac failure (acute or chronic) and of therapeutic approaches (medical or surgical) makes necessary the integration within the same structure of the various experts involved in the diagnosis and the treatment of cardiac diseases. Technologic and human resources required to offer all the options represent a multifaceted commitment which should be focused optimally in dedicated centers. In these centers, collaboration should replace competition between the medical and the surgical cardiac specialists. Development of team work should permit to optimize the cost efficacy of the treatments. Most of all, such a structure will facilitate the translation of innovative therapies between the research centers and clinical facilities.

关键词: cardiac failure     cardiac transplantation     mechanical circulatory support    

Association of cardiac disease with the risk of post-lung transplantation mortality in Chinese recipients

《医学前沿(英文)》 2023年 第17卷 第1期   页码 58-67 doi: 10.1007/s11684-022-0937-y

摘要: The current organ allocation rules prioritize elderly and urgent patients on the lung transplantation (LT) waiting list. A steady increase in the threshold at which age is taken into consideration for LT has been observed. This retrospective cohort study recruited 166 lung transplant recipients aged 65 years between January 2016 and October 2020 in the largest LT center in China. In the cohort, subgroups of patients aged 65–70 years (111 recipients, group 65–70) and 70 years (55 recipients, group 70) were included. Group D restrictive lung disease was the main indication of a lung transplant in recipients over 65 years. A significantly higher percentage of coronary artery stenosis was observed in the group 70 (30.9% vs. 14.4% in group 65–70, P = 0.014). ECMO bridging to LT was performed in 5.4% (group 65–70) and 7.3% (group 70) of patients. Kaplan–Meier estimates showed that recipients with cardiac abnormalities had a significantly increased risk of mortality. After adjusting for potential confounders, cardiac abnormality was shown to be independently associated with the increased risk of post-LT mortality (HR 6.37, P = 0.0060). Our result showed that LT can be performed in candidates with an advanced age and can provide life-extending benefits.

关键词: cardiac disease     mortality     aged population     lung transplantation    

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

null

《医学前沿(英文)》 2014年 第8卷 第2期   页码 254-258 doi: 10.1007/s11684-014-0319-1

摘要:

Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma. It can progress to leukemic phase but frank leukemic picture at initial presentation is not common. Leukemic phase indicates advance stage of the disease and generally associated with extensive extra-nodal involvement. Pericardial invasion has been reported, however we could not find a report of myocardial infiltration by this disease since the appraisal of the term “mantle cell lymphoma” in 1992. Here we report a case of cardiac involvement by mantle cell leukemia leading to cardiogenic shock which complicates the treatment decisions.

关键词: mantle cell lymphoma     bendamustine     cardiogenic shock    

Effects of RNA interference targeting angiotensin 1a receptor on blood pressure and cardiac hypertrophy

ZHANG Jingqun, SUN Honglei, MA Yexin, WANG Daowen

《医学前沿(英文)》 2008年 第2卷 第1期   页码 19-24 doi: 10.1007/s11684-008-0005-2

摘要: The aim of this study is to investigate the effects of RNA interference (RNAi) targeting angiotensin 1a receptor (AT1a) on blood pressure and cardiac hypertrophy of rats with renovascular hypertension. Two RNAi plasmids, pAT1a-shRNA1 and pAT1a-shRNA2 each carrying a U6 promoter and an AT1a-specific shRNA-coding template sequence corresponding to the sites 928–946, 978–996 of the mRNA transcript, and a control plasmid pCon carrying a nonspecific shRNA-coding sequence were constructed. Thirty Sprague – Dawley rats with renovascular hypertension (2-kidney 1-clip) were randomly divided into 5 equal groups: Control group (without any intervention), pAT1a-shRNA1, pAT1a-shRNA2, pCon groups (with injection of the corresponding plasmid 4 mg/kg respectively into the tail vein), and valsartan group (30 mg/kg·d by gavage). Three weeks after drug administration, pAT1a-shRNA1, pAT1a-shRNA2 and valsartan respectively resulted in decrease of the tail blood pressure by (15.1 ± 5.4), (16.4 ± 8.4) and (30.6 ± 18.2) mmHg. However, the tail blood pressure increased further by about 25 mmHg in both of pCon and control groups. The carotid artery pressures of pAT1a-shRNA1, pAT1a-shRNA2 and valsartan groups were all significantly lower than those of the control and pCon groups. The ratio of left ventricle weight to body weight (LV/BW) of the rats in pAT1a-shRNA1, pAT1a-shRNA2, and valsartan groups decreased significantly than in the control group ( < 0.01), similar to those of the normal SD rats( > 0.05). Histopathological examination showed that the myocardiocytes were significantly hypertrophic and the basal membrane of the aorta was significantly thickened in the control group and such changes were alleviated in the pAT1a-shRNA1, pAT1a-shRNA2 and valsartan groups. Compared with the control group, pAT1a-shRNA1 and pAT1a-shRNA2 groups had lowered expression of AT1 receptor (in the myocardium and the thoracic aorta (all < 0.01); however, there were no significant differences in expression levels of AT1 receptor in valsartan and the control groups ( > 0.05). We conclude that RNAi targeting AT1a receptor inhibits the development of renovascular hypertension and the accompanying cardiac hypertrophy. RNAi technology may become a new strategy of gene therapy for hypertension.

关键词: therapy     Sprague     administration     cardiac hypertrophy     valsartan    

Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis

null

《医学前沿(英文)》 2014年 第8卷 第4期   页码 445-455 doi: 10.1007/s11684-014-0378-3

摘要:

Recent evidences suggested that cyclic guanosine monophosphate-specific phosphodiesterase 5 (PDE5) inhibitor represents an important therapeutic target for cardiovascular diseases. Whether and how it ameliorates cardiac fibrosis, a major cause of diastolic dysfunction and heart failure, is unknown. The purpose of this study was to investigate the effects of PDE5 inhibitor on cardiac fibrosis. We assessed cardiac fibrosis and pathology in mice subjected to transverse aortic constriction (TAC). Oral sildenafil, a PDE5 inhibitor, was administered in the therapy group. In control mice, 4 weeks of TAC induced significant cardiac dysfunction, cardiac fibrosis, and cardiac fibroblast activation (proliferation and transformation to myofibroblasts). Sildenafil treatment markedly prevented TAC-induced cardiac dysfunction, cardiac fibrosis and cardiac fibroblast activation but did not block TAC-induced transforming growth factor-β1 (TGF-β1) production and phosphorylation of Smad2/3. In isolated cardiac fibroblasts, sildenafil blocked TGF-β1-induced cardiac fibroblast transformation, proliferation and collagen synthesis. Furthermore, we found that sildenafil induced phosphorylated cAMP response element binding protein (CREB) and reduced CREB-binding protein 1 (CBP1) recruitment to Smad transcriptional complexes. PDE5 inhibition prevents cardiac fibrosis by reducing CBP1 recruitment to Smad transcriptional complexes through CREB activation in cardiac fibroblasts.

关键词: PDE5     cardiac fibrosis     TGF-β     CREB    

Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast

Xuran Chu, Chengshui Chen, Chaolei Chen, Jin-San Zhang, Saverio Bellusci, Xiaokun Li

《医学前沿(英文)》 2020年 第14卷 第3期   页码 262-272 doi: 10.1007/s11684-019-0717-5

摘要: Regeneration carries the idea of regrowing partially or completely a missing organ. Repair, on the other hand, allows restoring the function of an existing but failing organ. The recognition that human lungs can both repair and regenerate is quite novel, the concept has not been widely used to treat patients. We present evidence that the human adult lung does repair and regenerate and introduce different ways to harness this power. Various types of lung stem cells are capable of proliferating and differentiating upon injury driving the repair/regeneration process. Injury models, primarily in mice, combined with lineage tracing studies, have allowed the identification of these important cells. Some of these cells, such as basal cells, broncho-alveolar stem cells, and alveolar type 2 cells, rely on fibroblast growth factor (FGF) signaling for their survival, proliferation and/or differentiation. While pre-clinical studies have shown the therapeutic benefits of FGFs, a recent clinical trial for acute respiratory distress syndrome (ARDS) using intravenous injection of FGF7 did not report the expected beneficial effects. We discuss the potential reasons for these negative results and propose the rationale for new approaches for future clinical trials, such as delivery of FGFs to the damaged lungs through efficient inhalation systems, which may be more promising than systemic exposure to FGFs. While this change in the administration route presents a challenge, the therapeutic promises displayed by FGFs are worth the effort.

关键词: FGF     human lung     repair     regeneration     stem cells    

Acetyl salicylic acid attenuates cardiac hypertrophy through Wnt signaling

null

《医学前沿(英文)》 2015年 第9卷 第4期   页码 444-456 doi: 10.1007/s11684-015-0421-z

摘要:

Ventricular hypertrophy is a powerful and independent predictor of cardiovascular morbid events. The vascular properties of low-dose acetyl salicylic acid (aspirin) provide cardiovascular benefits through the irreversible inhibition of platelet cyclooxygenase 1; however, the possible anti-hypertrophic properties and potential mechanism of aspirin have not been investigated in detail. In this study, healthy wild-type male mice were randomly divided into three groups and subjected to transverse aortic constriction (TAC) or sham operation. The TAC-operated mice were treated with the human equivalent of low-dose aspirin (10 mg·kg−1·d−1); the remaining mice received an equal amount of phosphate buffered saline with 0.65% ethanol, which was used as a vehicle. A cardiomyocyte hypertrophy model induced by angiotensin II (10 nmol·L−1) was treated with the human equivalent of low (10 or 100 µmol·L−1) and high (1000 µmol·L−1) aspirin concentrations in plasma. Changes in the cardiac structure and function were assessed through echocardiography and transmission electron microscopy. Gene expression was determined through RT-PCR and western blot analysis. Results indicated that aspirin treatment abrogated the increased thickness of the left ventricular anterior and posterior walls, the swelling of mitochondria, and the increased surface area in in vivo and in vitro hypertrophy models. Aspirin also normalized the upregulated hypertrophic biomarkers, β-myosin heavy chain (β-MHC), atrial natriuretic peptide (ANP), and b-type natriuretic peptide (BNP). Aspirin efficiently reversed the upregulation of β-catenin and P-Akt expression and the TAC- or ANG II-induced downregulation of GSK-3β. Therefore, low-dose aspirin possesses significant anti-hypertrophic properties at clinically relevant concentrations for anti-thrombotic therapy. The downregulation of β-catenin and Akt may be the underlying signaling mechanism of the effects of aspirin.

关键词: aspirin     Akt     cardiac hypertrophy     GSK-3β     Wnt/β-catenin    

PAK1 is a novel cardiac protective signaling molecule

null

《医学前沿(英文)》 2014年 第8卷 第4期   页码 399-403 doi: 10.1007/s11684-014-0380-9

摘要:

We review here the novel cardiac protective effects of the multifunctional enzyme, p21-activated kinase 1 (PAK1), a member of a serine/threonine protein kinase family. Despite the large body of evidence from studies in noncardiac tissue indicating that PAK1 activity is key in the regulation of a number of cellular functions, the role of PAK1 in the heart has only been revealed over the past few years. In this review, we assemble an overview of the recent findings on PAK1 signaling in the heart, particularly its cardiac protective effects. We present a model for PAK1 signaling that provides a mechanism for specifically affecting cardiac cellular processes in which regulation of protein phosphorylation states by protein phosphatase 2A (PP2A) predominates. We discuss the anti-adrenergic and antihypertrophic cardiac protective effects of PAK1, as well as its role in maintaining ventricular Ca2+ homeostasis and electrophysiological stability under physiological, β-adrenergic and hypertrophic stress conditions.

关键词: p21-activated kinase 1 (PAK1)     heart    

FGF23 associated bone diseases

null

《医学前沿(英文)》 2013年 第7卷 第1期   页码 65-80 doi: 10.1007/s11684-013-0254-6

摘要:

Recently, fibroblast growth factor 23 (FGF23) has sparked widespread interest because of its potential role in regulating phosphate and vitamin D metabolism. In this review, we summarized the FGF superfamily, the mechanism of FGF23 on phosphate and vitamin D metabolism, and the FGF23 related bone disease.

关键词: fibroblast growth factor 23     FGF receptor     phosphate metabolism     Klotho     bone disease    

Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology

null

《医学前沿(英文)》 2013年 第7卷 第1期   页码 25-30 doi: 10.1007/s11684-013-0244-8

摘要:

Fibroblast growth factor 21 (FGF21) is a member of the fibroblast growth factor family. It actually functions as endocrine hormones but does not regulate cell growth and differentiation. It is demonstrated that FGF21 acts on multiple tissue to coordinate carbohydrate and lipid metabolism, including enhancing insulin sensitivity, decreasing triglyceride concentrations, causing weight loss, ameliorating obesity-associated hyperglycemia and hyperlipidemia. Moreover, FGF21 also plays important roles in some physiological processes, such as fasting and feeding, growth hormone axis and thermogenic function of brown adipose tissue. Clinical relevance of FGF21 in humans is still unclear, and the basis and consequences of increased FGF21 in metabolic disease remain to be determined. Both the pharmacological actions and physiological roles make FGF21 attractive drug candidates for treating metabolic disease, but some questions remain to be answered. This article concentrates on recent advances in our understanding of FGF21.

关键词: FGF21     metabolism     pharmacology     physiology     clinical relevance    

Right coronary occlusion following transcatheter aortic valve implantation: two case reports

null

《医学前沿(英文)》 2016年 第10卷 第3期   页码 351-355 doi: 10.1007/s11684-016-0465-8

摘要:

This paper discusses two male patients with severe aortic stenosis, whose right coronary arteries (RCA) were completely occluded during transcatheter aortic valve implantation (TAVI), leading to fatal hemodynamic disorder. Occlusions of RCA complicated by TAVI are rare. In addition, emergency cardiopulmonary bypass (CPB) played a critical role in rescuing our second patient. Both patients were admitted for “severe aortic stenosis,” and TAVIs were performed. The first patient’s blood pressure immediately dropped to 70/40 mmHg after the balloon expansion and did not increase much after the administration of aramine or fluid therapy. He did not receive emergency surgery and died after 1.5 h of resuscitation. The second patient’s blood pressure fluctuated greatly for several minutes after the valve implantation, ranging from 170/100 mmHg to 60/40 mmHg. Angiography revealed a total occlusion of RCA. Thoracic surgery with CPB was performed, and the patient survived.

关键词: aortic stenosis     transcatheter aortic valve implantation     right coronary occlusion     cardiac group    

Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications

null

《医学前沿(英文)》 2016年 第10卷 第1期   页码 33-40 doi: 10.1007/s11684-016-0431-5

摘要:

Breast cancer is the most common malignant tumor in women, and the incidence of this disease has increased in recent years because of changes in diet, living environment, gestational age, and other unknown factors. Previous studies focused on cancer cells, but an increasing number of recent studies have analyzed the contribution of cancer microenvironment to the initiation and progression of breast cancer. Cancer-associated fibroblasts (CAFs), the most abundant cells in tumor stroma, secrete various active biomolecules, including extracellular matrix components, growth factors, cytokines, proteases, and hormones. CAFs not only facilitate the initiation, growth, angiogenesis, invasion, and metastasis of cancer but also serve as biomarkers in the clinical diagnosis, therapy, and prognosis of breast cancer. In this article, we reviewed the literature and summarized the research findings on CAFs in breast cancer.

关键词: cancer-associated fibroblast     breast cancer     progression     prognosis    

心肌远程调节及其临床相关性:现在一起来! Review

Kristin Luther,Yang Song,Yang Wang,Xiaoping Ren,W. Keith Jones

《工程(英文)》 2015年 第1卷 第4期   页码 490-499 doi: 10.15302/J-ENG-2015117

摘要:

急性心肌梗死(AMI) 是世界上致死和致残的主要病因。及时再灌注法是AMI的标准疗法,能够缩小梗死面积,提高患者存活率和改善预后。然而,25 %的患者在患心肌梗死(Ml) 后会进一步发展成为心力衰竭(HF),且其中50%的患者会在5年内死亡。由于梗死面积是预断病人病情( 包括HF的形成) 的主要指标,因此,改善心肌的治疗方法具有极大的应用前景。 在过去30年中,研究者已发现多种能够刺激内源性心肌保护通道的刺激物,这些刺激物能在缺血预适应(IPC)和缺血后适应以及心肌缺血情况下启动保护机制。当在心肌缺血发生前、发生期间或发生后即刻使用刺激物,在远离心脏的血管床中发生的短暂、可逆性局部缺血就会即刻引发心肌保护机制——这种现象被分别称为远程缺血预适应,远程缺血期适应和远程缺血后适应。尽管目前的研究尚未完全阐明远程缺血预适应(RIPC) 的作用机制,但RIPC与IPC在机制上有很多共同之处。RIPC的发现使研究转向了远程非缺血刺激的应用,包括神经刺激( 脊髓刺激和迷走神经刺激) 以及电针(EA)。笔者与其他研究人员发现并阐述了非缺血现象的机制,并将其定义为远程创伤预适 应(RPCT)。通过刺激皮肤感觉神经来启动RPCT,这与穴位处神经刺激和EA既有相似性又有一定差异性。笔者在此次研究中还发现,可通过采用腹中线电刺激(与EA疗法相似) 来模拟RPCT,而且作为预适应刺激和后适应刺激( 在应用再灌注法时),这种激活心肌保护机制的模式是非常有效的。通过对这些心肌保护现象的研究,学术界对心肌保护机制形成了一种全面且综 合的理解,而且在过去的5~10 年期间, 这种理解变得逐渐清晰,即无论是缺血性刺激诱导还是非缺血性刺激诱导,其机制均相似。通过对文献中多种数据的综合考虑,我们认为所有的这些心肌保护“适应”现象均表示心肌保护机制的启动是从心肌适 应网(含有特定介质和心肌细胞生存感受器) 的不同切入点进行的,该切入点包括NF-κB、Stat3/5、蛋白激酶C、舒缓激肽和mitoKATP 通道。神经系统传导通路可能代表了一种激活心脏和其他器官适应的新机制。研究表明,由于IPC和RIPC存在一定风险并且无法应用于某些患者,所以它们很难被转化为临床应用。因此,近期又新兴了一种神经刺激和痛感刺激的应用,这是一种激活心肌适应的潜在的非缺血性无创方法。作为引起心脏保护作用众多方法之一的后适应重点强调了临床相关性,这种临床相关性有助于在现有成熟的药物与电子疗法中加速新的治疗方向的突破。

关键词: 远程心肌保护     心肌适应     非缺血性适应     末端疼痛性刺激     神经和分子机制     临床可行性     电子疗法    

Familial amyloid cardiomyopathy masquerading as chronic Guillain-Barre syndrome: things are not always what they seem

null

《医学前沿(英文)》 2017年 第11卷 第2期   页码 293-296 doi: 10.1007/s11684-017-0516-9

摘要:

Familial amyloid cardiomyopathy is a challenging condition that mimics many other diseases, particularly in patients with pronounced neurological presentations and unexplained or equivocal cardiac abnormalities. In this case, a 57-year-old man was admitted for outpatient cardiological evaluation of progressive right heart failure and limb paraesthesias. The patient presented with hypertension, chronic Guillain-Barre syndrome, and sick sinus syndrome. Transthoracic echocardiograms showed a thickened ventricular wall and enlarged atrium. Tissue Doppler showed a restrictive filling pattern. Transthyretin (TTR)-associated amyloidosis, which was revealed by abdominal fat-pad biopsy and DNA analysis, explained the concurrence of independent pathological features, including neuropathy and cardiac involvement. Genetic testing identified a G>T mutation in exon 4 of the transthyretin (TTR) gene. This mutation resulted in the alanine-to-serine substitution at amino acid position 117. Moreover, genetic testing confirmed that the patient’s asymptomatic son carried the same amyloidogenic TTR mutation. Given these findings, the diagnosis of familial amyloid cardiomyopathy, which was misdiagnosed as chronic Guillain-Barre syndrome, was proposed.

关键词: transthyretin (TTR) cardiac amyloidosis     sick sinus syndrome     chronic Guillain-Barre syndrome    

标题 作者 时间 类型 操作

Distinct mononuclear diploid cardiac subpopulation with minimal cell–cell communications persists in

期刊论文

Integrated management of cardiac failure: the cardiac failure clinic

null

期刊论文

Association of cardiac disease with the risk of post-lung transplantation mortality in Chinese recipients

期刊论文

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

null

期刊论文

Effects of RNA interference targeting angiotensin 1a receptor on blood pressure and cardiac hypertrophy

ZHANG Jingqun, SUN Honglei, MA Yexin, WANG Daowen

期刊论文

Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis

null

期刊论文

Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast

Xuran Chu, Chengshui Chen, Chaolei Chen, Jin-San Zhang, Saverio Bellusci, Xiaokun Li

期刊论文

Acetyl salicylic acid attenuates cardiac hypertrophy through Wnt signaling

null

期刊论文

PAK1 is a novel cardiac protective signaling molecule

null

期刊论文

FGF23 associated bone diseases

null

期刊论文

Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology

null

期刊论文

Right coronary occlusion following transcatheter aortic valve implantation: two case reports

null

期刊论文

Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications

null

期刊论文

心肌远程调节及其临床相关性:现在一起来!

Kristin Luther,Yang Song,Yang Wang,Xiaoping Ren,W. Keith Jones

期刊论文

Familial amyloid cardiomyopathy masquerading as chronic Guillain-Barre syndrome: things are not always what they seem

null

期刊论文